RKDANasdaqCrude Petroleum & Natural GasFiscal year ends December 31
Arcadia Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.14−0.02 (-12.01%)
Close on Oct 19, 2026
- Market cap
- $433.92K
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2013 to 2025
Gross margin
36.2%+0.9 pts over 5 years
Operating margin
-51.5%+107.6 pts over 5 years
Net margin
-48.1%+9.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -3.7% | -13.2% | -9.6% | -1.1% | |
| Gross profit | -15.5% | +10.1% | -9.1% | -9.0% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -62.9% | -26.3% | – | |
| Return on assets | -30.0% | -11.6% | -23.3% | |
| Current ratio | 16.69 | 5.02 | 3.09 | |
| Debt to equity | 1.13 | 0.12 | – | |
| Interest coverage | -14.1× | -271.9× | – | |
| Inventory turnover | 3.3× | 1.9× | 2.9× | |
| Capex to revenue | 7.2% | 29.1% | 0.0% | |
| Diluted shares | 0M | 0M | 1M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Arcadia Biosciences generated $69.47M from operations and spent $1.10M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$69.47M
Used
$1.10M
Capital expenditure$1.10M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-139.5%
×Asset turnover0.30×
×Equity multiplier1.74×
=Return on equity, FY2024-73.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2024 | -139.5% | 0.30× | 1.74× | -73.8% |
| FY2023 | -313.9% | 0.18× | 1.44× | -82.5% |
| FY2022 | -207.3% | 0.20× | 1.40× | -59.0% |
| FY2021 | -216.2% | 0.15× | 1.55× | -49.8% |
| FY2020 | -57.9% | 0.20× | 2.26× | -26.3% |
| FY2019 | -2464.1% | 0.04× | 2.76× | -280.8% |
| FY2018 | -920.8% | 0.07× | 1.95× | -129.5% |
| FY2017 | -390.1% | 0.11× | 2.42× | -104.0% |
| FY2016 | -615.6% | 0.05× | 2.10× | -62.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$2.34M
- Cash generatingOperating cash flow above zero-$4.70M
- Return on assets improvedROA up on the prior year-35.7% → -17.3%
- Earnings backed by cashOperating cash flow above net income-$4.70M vs -$2.34M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.61 → 3.09
- No dilutionShare count did not rise1M → 1M
- Gross margin improvedGross margin up on the prior year41.27% → 36.23%
- More efficientAsset turnover rose0.26 → 0.36